88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026 Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 ... 2026-09-01T Biotechnology Medical/Pharmaceuticals
Suki Named a Transformational Innovation Leader in Ambient Clinical Intelligence by Frost & Sullivan 2026 recognition highlights Suki's innovation, clinical quality and measurable impact as Ambient Clinical Intelligence expands across the enterprise ... 2026-09-01T Computer Software Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora ... 2026-09-01T Biotechnology Cosmetics & Personal Care Medical/Pharmaceuticals
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development NANJING, China , Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel ROCKVILLE, Md. , Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia Spotlights how scaling AI and big data can make clinical pathways more efficient Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast ... 2026-09-01T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals Trade show news
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis "From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75% [1] , [2] " ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Company to host a corporate update call Tuesday, September 1st at 8:00am ET ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved